Abstract:Background: The signal transducers and activators of transcription 3 (STAT3) signaling pathway plays important roles in oncogenesis, angiogenesis, immunity, and tumor cell invasion. In the present study, we investigated the association of interleukin (IL)-6/STAT3 signaling pathway with T lymphocytes and clinical implication in patients with gastric cancer.Methods: Seventy one patients who underwent gastrectomy due to gastric adenocarcinoma were studied. Blood samples were collected before and after surgical gastrectomy to quantify the levels of IL-6, IL-10 and VEGF using an enzyme-linked immunosorbent assay, as well as T lymphocyte subsets (CD3(+), CD4(+), CD8(+), CD4(+)/CD8(+)) and natural killer (NK) cells by a flow cytometry. Furthermore, the expression of IL-6, survivin, STAT3, STAT3 phosphorylation (p-STAT3), and VEGF were determined in human gastric cancer and adjacent normal mucosa through Western blot and immunohistochemistry.Results: Postoperative levels of IL-6, IL-10 and VEGF in serum were significantly lower than preoperative levels. Percentages of T-cell subsets and NK cells in blood were significantly increased after postoperative-week 1 as compared to preoperative group, which was further augmented at 1 month after gastrectomy. In addition, the expression of IL-6, survivin, STAT3, p-STAT3, and VEGF were increased in human gastric cancer tissues as compared to adjacent normal mucosa. Their expression was associated with TNM stage of gastric cancer. The level of STAT3 activation in clinical samples was correlated with IL-6 expression. All gastric tumor samples, which expressed p-STAT3, also expressed IL-6 with weak expression detected in adjacent normal mucosa.Conclusion: Increased IL-6-induced activation of STAT3 was observed in neoplastic gastric tissue, which positively correlated with tumor progression. Moreover, IL-6 and STAT3 downstream signals such as IL-10 and VEGF were reduced in patients after removal of gastric cancer as compared to pre-operation. Therefore, inhibition of the IL-6/STAT3 signaling pathway may provide a new therapeutic strategy against gastric cancer.

STAT3 aggravates TGF-β1 induced epithelial-to-mesenchymal transition in hepatocellular carcinoma cells

STAT3 Aggravates TGF-β1-induced Hepatic Epithelial-to-mesenchymal Transition and Migration.

STAT3 Activation Mediates Epithelial-to-mesenchymal Transition in Human Hepatocellular Carcinoma Cells.

JAK/STAT3 Signaling is Required for TGF-β-induced Epithelial-Mesenchymal Transition in Lung Cancer Cells.

Aberrantly Expressed Fra-1 by Il-6/Stat3 Transactivation Promotes Colorectal Cancer Aggressiveness Through Epithelial-Mesenchymal Transition

Infiltrating Regulatory T Cells Promote Invasiveness of Liver Cancer Cells Via Inducing Epithelial-Mesenchymal Transition

The Effects and Mechanisms of Blockage of Stat3 Signaling Pathway on Il-6 Inducing Emt in Human Pancreatic Cancer Cells in Vitro

Interference of Suppressor of Cytokine Signaling 3 Promotes Epithelial-Mesenchymal Transition in MHCC97H Cells

TGF-β1 induced deficiency of linc00261 promotes epithelial–mesenchymal-transition and stemness of hepatocellular carcinoma via modulating SMAD3

IL-6 Upregulates the Expression of IL-6R Through the JAK2/STAT3 Signalling Pathway to Promote Progression of Hepatocellular Carcinoma

TLX3 Repressed SNAI1-induced Epithelial-Mesenchymal Transition by Directly Constraining STAT3 Phosphorylation and Functionally Sensitized 5-FU Chemotherapy in Hepatocellular Carcinoma

Activation of STAT3 in Human Gastric Cancer Cells Via Interleukin (Il)-6-type Cytokine Signaling Correlates with Clinical Implications

Reduced N-acetylglucosaminyltransferase III Expression Via Smad3 and Erk Signaling in TGF-β1-induced HCC EMT Model.

Hyperactivation of IL-6/STAT3 Pathway Leaded to the Poor Prognosis of Post-Tace HCCs by HIF-1α/SNAI1 Axis-Induced Epithelial to Mesenchymal Transition

The Effects and Mechanism of IL-6 on the Epithelial to Mesenchymal Transition of Pancreatic Cancer Cells

Cancer-associated Fibroblasts induce epithelial-mesenchymal transition <i>via</i> the Transglutaminase 2-dependent IL-6/IL6R/STAT3 axis in Hepatocellular Carcinoma

KIAA1217 Promotes Epithelial-Mesenchymal Transition and Hepatocellular Carcinoma Metastasis by Interacting with and Activating STAT3

Interleukin-6 Induced Proliferation Is Attenuated by Transforming Growth Factor-β-Induced Signaling in Human Hepatocellular Carcinoma Cells

Smad2/3/4 Pathway Contributes to TGF-β-Induced MiRNA-181b Expression to Promote Gastric Cancer Metastasis by Targeting Timp3

SHC4 promotes tumor proliferation and metastasis by activating STAT3 signaling in hepatocellular carcinoma

STMN2 mediates nuclear translocation of Smad2/3 and enhances TGF signaling by destabilizing microtubules to promote epithelial-mesenchymal transition in hepatocellular carcinoma